Bamberg Health’s Post

See this interesting Opinion Piece in DagensMedicin where industry leaders from Gilead Sciences Clemens Schödl, Jannsen Julie Enevold Brooker, Sanofi Daniel Sandgren Danish Chamber of Commerce (Dansk Erhverv) Katrina Feilberg offer their perspective on what it would take to make a new Danish strategy for personalized medicine a success. https://lnkd.in/dvtwch6h #personligmedicin #GileadNordics #mycompany

🌍✨ We have successfully completed our first clinical trial beyond our borders, collaborating with the Clínica FOSCAL team in Colombia! 🇨🇱🇨🇴 In simple terms, we isolated umbilical cord cells from newborns in Chile, expanded them in our Cells for Cells GMP lab, and shipped them to Colombia for this study. This clinical collaboration explored the potential of umbilical cord mesenchymal stromal cells (UC-MSCs) in treating knee #osteoarthritis (OA). Our randomized, double-blind pilot study demonstrated that a single injection of Cellistem™OA significantly improved pain, stiffness, and overall function in patients—outperforming traditional corticosteroid treatments—all with a strong safety profile and no severe adverse events. A big shoutout to the committed teams of Clinicians and Scientists #Colombia and #Chile for making this possible. 🖇 link of the original article published in Cytotherapy https://lnkd.in/eqBkX4UZ #ClinicalTrial #InternationalCollaboration #Osteoarthritis #cellandgenetherapy #stemcells #StemCellTherapy #CellistemOA

Advancing Sustained Release to Ease the Burden of Acute Therapies On World Sight Day, we want to recognize the importance of advancing treatments that can help improve the quality of life for patients with vision-related conditions. We’re excited to highlight our recent partnership with Re-Vana Therapeutics, pioneers in sustained-release technologies for a range of eye diseases, designed to reduce the frequency of injection into the eye and ease the burden on both patients and healthcare systems. Our latest article features insights from Patrick Ruane, Chief Operating Officer at Re-Vana Therapeutics, and experts from Cambridge Design Partnership: Dariusz Żak, Head of Applied Science, and Fran Pencliffe, Consultant Healthcare Devices Engineer. In the article, we explore: • The Rise of Targeted Combination Products • Enhancing Patient Care Through Sustained Release and User-Centered Design • Driving Innovation Through Agility, Expertise, and Collaboration Read the full article here: https://lnkd.in/d4ujuv-z #WorldSightDay #DrugDelivery #HealthcareInnovation #Ophthalmology

𝐁𝐢𝐨𝐡𝐨𝐩𝐞 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 €𝟐𝐌 𝐆𝐫𝐚𝐧𝐭 𝐟𝐨𝐫 𝐌𝐓𝐗-𝐂𝐄𝐋𝐋 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭   ⚫ Spanish biotech company Biohope has received a €2 million grant from the Comunidad de Madrid to advance its diagnostic device, MTX-CELL, which predicts Methotrexate (MTX) efficacy in Rheumatoid Arthritis (RA) patients. This groundbreaking tool enables personalized treatments, improving outcomes and reducing healthcare costs.   ⚪ The grant, part of the Seal of Excellence initiative by the 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐂𝐨𝐮𝐧𝐜𝐢𝐥 (𝐄𝐈𝐂) 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐨𝐫, recognizes high-quality projects. ARISTOS Innovation Funding by PNO Innovation (Spain) played a key role in helping Biohope achieve this prestigious recognition! 🔵 With this funding, #Biohope will finalize and validate MTX-CELL, bringing it closer to clinical practice and benefiting patients, providers, and healthcare systems alike. 𝐌𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 👉🏾 https://lnkd.in/dgCFB2Wy #Aristos #PNOSpain #PNOGroup #EICAccelerator

This is a game-changer for the DTx market. Bayer becomes the first big pharma company to enter the German DiGA landscape through the acquisition of Cara Care, a CE-certified medical device. CC is the first reimbursable DiGA for irritable bowel syndrome (IBS), offering patients a comprehensive, guideline-based therapeutic option. IBS affects approximately 11.1% of Germany’s population and poses significant treatment challenges due to its complex pathophysiology and variable symptoms. David Evendon-Challis, Head of R&D at Bayer’s Consumer Health division, commented: “With Cara Care, we’re providing patients with a tool to better understand and manage their IBS. This milestone advances our strategy to deliver precision health solutions that empower patients while supporting HCPs in delivering effective care.” This proves that scientifically backed digital therapies work. Source: https://lnkd.in/desUjfR7

Let's hope for more instances of big pharma like Bayer supporting new modes of care! 🤳 💻 🧬 🩻 According to the PR: "Additionally, Bayer plans to expand its engagement in the area of digital health products with the acquisition and contribute to the market of self-medication, which has been growing steadily since the pandemic." The skeptic could say it reads: "People are going to do weird stuff and we want to make money on that too!" But I see it as an opportunity for the innovation ecosystem to provide novel, more patient- and provider- centric solutions, focused on prevention and self-help and backed by solid evidence, to compete for some pharma money. Pharma sees the tide shifting towards diversification of care and the new options will be only as good as we make them. #DTx #DiGA #GI #IBS #Bayer #CaraCare

Access to innovative medicines varies across Europe. According to a NIHE report on Advanced Therapy Medicinal Products (ATMPs) in England, Sweden, Norway, and Denmark, notable differences exist: 1.     Some countries are more attractive to pharmaceutical companies than others. For instance, all ATMPs approved by the European Medicines Agency (EMA), including their indications, were applied in England, whereas only about half were applied in Denmark. 2.     Certain health technology assessment (HTA) bodies seem more successful at securing financial agreements with pharmaceutical companies. In England, ATMPs applied were approx. 50% more likely to be recommended compared to Norway and Sweden.   #NIHE #Sundpol #LIFSweden https://lnkd.in/dCAnfzfp https://lnkd.in/djqQ543e #NIHE #Sundpol #LIFSweden https://lnkd.in/dCAnfzfp https://lnkd.in/djqQ543e

Day 2 Highlight at World Orphan Drug Congress in Boston 🌐 Industry insights on partnering in the rare disease space struck a chord with us. Panelists discussed the advantages of partnerships between large and small biopharma and pharma companies. While established organizations can bring more resources to the development of medical treatments, smaller companies often have a deeper understanding of rare diseases and innovative approaches to problem-solving. 💡 Our agile team at Alethium Health has designed our clinical trial platform to anticipate nuanced needs and challenges before they happen. We’ve optimized trials by adjusting for patient or caregiver struggles, such as incorporating televisits and providing additional translations, to make clinical trials globally accessible at exceptional speed, reduced costs, and minimal risk. 🚀 #ClinicalTrials #OrphanDrugCongressUSA #DigitalClinicalTrials #RareDisease

🌍🧬 Revisiting a Landmark in Precision Medicine: Pharmacogenetics in Primary Care 🧬🌍 We’re revisiting a pivotal study from Family Practice that continues to influence the field of precision medicine today: "Improving prescribing: A feasibility study of pharmacogenetic testing with clinical decision support in primary healthcare in Singapore." 📌 Why revisit this research? This study set the stage for demonstrating the transformative power of pharmacogenetic testing integrated with clinical decision support systems (CDSS). Its insights remain vital for advancing healthcare globally. ✨ Key Takeaways: 🧬 Precision Focus: Showcased how pharmacogenomics can improve healthcare outcomes. 🌏 Global Relevance: Conducted in Singapore’s primary care setting, proving its universal applicability. 🤝 Expert Collaboration: Featuring contributions from Dr. Martin Dawes (The University of British Columbia) and Hagit Katzov-Eckert (GenXys Health Care Systems). At GenXys, we are proud to uphold and build upon the principles highlighted in this research—empowering healthcare professionals to optimize prescribing decisions and improve patient outcomes. 📖 Read the full study in the link below: https://lnkd.in/gSbvSk4h 🚀 Precision prescribing isn’t just the future—it’s here. Together, we can continue to innovate. #PrecisionMedicine #Pharmacogenomics #GenXys #CDSS #BetterPrescribing #PatientCare

🌟 J&J: A Decade of Innovation and Growth 🌟 💡 $57 Billion in Innovative Medicine Sales in 2024 📈 4% YoY Growth | 6% CAGR (2014–2024) Following yesterday's release of J&J's Q4 2024 data, we wanted to highlight the consistent growth of their Innovative Medicine segment, which has reached its highest sales in a decade at ~$57 billion. 📣 Stay tuned! We'll be sharing a follow-up post diving into the subcategories, zooming in on the oncology segment, and exploring the key contributors to this incredible growth. 🔍 Your Take: What are your thoughts on J&J's journey? Can it sustain this momentum? Let's discuss! #Healthcare #Innovation #Pharma Johnson & Johnson Innovative Medicine Johnson & Johnson #Strategy #RanunculusHill